Abstract

Background: Iatrogenic esophageal perforation represents a catastrophic complication of endoscopic retrograde cholangiopancreatography with mortality rates reaching 10-25%, yet therapeutic options remain limited to surgical intervention and supportive care. The absence of targeted pharmacological therapies for tissue repair, infection prevention, and inflammation modulation in gastrointestinal perforations reflects broader challenges in pharmaceutical development, including prolonged discovery timelines averaging 12-15 years, high clinical attrition rates exceeding 90%, and inadequate translation of preclinical findings to clinical efficacy. Current drug discovery paradigms face substantial obstacles in identifying and validating therapeutic targets for acute surgical complications and developing agents that promote accelerated tissue healing while preventing septic complications. 
Aim: This article examines innovative pharmaceutical development strategies applicable to acute gastrointestinal injuries, linking clinical management of iatrogenic esophageal perforation with contemporary drug discovery approaches including high-throughput screening, computational target identification, and translational research frameworks. 
Discussion: Modern drug development increasingly employs high-throughput screening platforms evaluating millions of compounds against validated biological targets, structure-based drug design leveraging three-dimensional protein structures, and systems biology approaches identifying network-level therapeutic opportunities. Target identification through genomic and proteomic profiling, coupled with advanced preclinical models recapitulating human tissue injury and repair, enables more predictive assessment of clinical translation. Lead optimization employs multi-parameter approaches simultaneously enhancing potency, selectivity, and pharmaceutical properties. 
Impact: Implementation of accelerated development strategies demonstrates substantial reductions in discovery timelines and improved clinical success rates, particularly for repurposed therapeutics and precision medicine applications targeting specific patient populations or injury mechanisms. 
Outlook: Future advancement requires integration of artificial intelligence-driven compound prediction, patient-specific biomarker development, organoid-based disease modeling, and adaptive clinical trial designs to optimize therapeutic development for acute surgical complications and critical care applications.